Heteroaromatic D1 Ligands Modulating Receptor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical agents fail to effectively modulate dopamine D1 receptors, leading to inadequate treatment of disorders associated with dysregulated D1 receptor activation, such as schizophrenia and cognitive impairments.
Innovation Solution
Development of specific heteroaromatic compounds, including those of Formula I-a, I-b, I-d, and I-e, which act as D1 receptor agonists or partial agonists, for use in treating disorders like schizophrenia, cognitive impairments, and Parkinson's disease by administering a therapeutically effective amount of these compounds to modulate D1 receptor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current pharmaceutical agents are used to modulate dopamine D1 receptors, then treatment of disorders associated with dysregulated D1 receptor activation is attempted, but the treatment effectiveness is inadequate
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of dopamine D1 receptor ligands through systematic variation of heteroaromatic ring systems, substituent groups, and molecular configurations. This enables optimization of binding affinity, selectivity, and pharmacological activity to achieve effective D1 receptor modulation for treating schizophrenia and cognitive impairments
2Adaptability or versatility
If heteroaromatic compounds of Formula I are developed as D1 receptor agonists, then D1 receptor modulation capability is improved, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex heteroaromatic compound structure into distinct modular components including core heteroaromatic rings (pyridine, pyrimidine, triazine), substituent groups (alkyl, alkoxy, halogen), and linkage moieties. This modular approach enables systematic optimization of D1 receptor binding properties while managing structural complexity through combinatorial design
Solution Approach 2:
The patent achieves universality by designing heteroaromatic compounds with multiple functional groups that can simultaneously provide D1 receptor binding, metabolic stability, and favorable pharmacokinetic properties. The core heteroaromatic structure serves multiple purposes including aromatic stacking interactions, hydrogen bonding capability, and structural rigidity
Data Source
AI summary
The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.